Diabetes drugs from Eli Lilly and Novo Nordisk, such as Mounjaro, Zepbound, Ozempic, and Wegovy, are expanding beyond ...

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

If you’ve spent any time in the real world lately, chances are you’ve heard of Ozempic, Wegovy, Mounjaro or semaglutide.

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...

Ozempic and Wegovy maker Novo Nordisk sees shares tumble on profit alert - The Danish firm blamed the move to slash its ...

Speakers at a congressional briefing on July 22 called on the FDA to take action against the marketing and distribution of ...

While Ozempic is effective at treating type 2 diabetes and supporting weight loss, it can also come with side effects.

U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...

The explosive popularity of GLP-1 weight-loss medications such as Ozempic®, Wegovy®, and Mounjaro® has transformed obesity care and created an unexpected cosmetic challenge. Rapid fat loss can leave ...